Revelation Biosciences Inc. Common Stock (REVB)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earning power, honest accounting, and a margin of safety. Revelation Biosciences is not there yet. It is a clinical-stage biotech with eight employees, no reported revenue in the filed periods I was given, and repeated losses. In fiscal Q2 2026, the quarter ended 2026-06-30, net income was -$3.3 million and diluted EPS was -$0.87. Fiscal Q1 2026, the quarter ended 2026-03-31, showed a -$3.0 million net loss. For FY2025, ended 2025-12-31, net income was -$8.9 million; FY2024, ended 2024-12-31, was -$15.0 million. Trailing free cash flow was -$9.4 million, a -324.6% FCF yield against a $2.9 million market cap. That is not a self-funding business. The balance sheet shows low D/E of 0.07, but FairStock's Altman Z-score of -4.59 and Piotroski F-score of 1/9 point to financial fragility. ROE is -154.77% and ROCE is -78.73%. There is no demonstrated moat; the entire option rests on Gemini/PHAD clinical data and future financing. At the 2026-10-13 close of $0.73, FairStock reports P/B of 0.28, P/E of 0.03, Graham Number of $39.61, and a 98.16% margin of safety, but those calculations sit awkwardly with the reported losses and cash burn. The Lynch category is none because the company lost money in each of the last four years. I would treat this as a speculative clinical bet, not a Graham-style bargain.

In plain English: Revelation Biosciences is a very small clinical-stage biotech with 8 employees, working on an inflammation treatment called Gemini. It has no revenue in the periods shown and has been losing money, including a $3.3 million loss in the quarter ended June 30, 2026. The stock price is at its 52-week low and some accounting measures make it look cheap, but the business is burning cash and has not proven it can make a profit.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer